Icon has reported net revenues of $229m for the first quarter of 2011, a 5% increase on the same period last year.
The company, which provides services to the pharmaceutical, biotechnology and medical device industries, said income from operations - before restructuring charges - was $16m compared to $26.8m for the same time last year.
During the months of January to March, the company undertook a number of cost reduction steps which led to restructuring costs of $5m.
Icon chief executive Peter Gray said that 2011 has started in line with expectations.
'With strong gross bookings of $329m, a strengthening pipeline of new opportunities and the Central Lab progressing as planned, we believe we are on track for a return to growth in the second half,' he added.
